The rejection may make the pharma firms remaining lawsuits more difficult. global health FDA HHS Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Breaking News Supreme Court rejects challenge to Medicare drug price negotiation Drugmakers have largely failed in suits against the program Manage alerts for this…
WASHINGTON — The Supreme Court on Monday dealt a major blow to the brand drug industry’s legal campaign against the Medicare drug price negotiation program.
The court declined to take up lawsuits against the program by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk. The justices did not give a reason for their decision.
The rejection was not a surprise. The drugmakers lost their appeals in lower courts, and the Supreme Court typically does not take up cases when there is agreement among lower courts.
Continue to STAT+ to read the full story…
US Pharma Marketing